HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer
Cancers · 06.11.2024 · 16 (22) · 3752
DOI: 10.3390/cancers16223752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 06.11.2024. Verfasst von Michela Cortesi und 14 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ricerca Corrente by the Italian Ministry of Health, Italian Ministry of Health.
Abstract (Originalsprache)
Background
Adjuvant trastuzumab is the standard of care for HER2+ breast cancer (BC) patients. However, >50% of patients become resistant. This study aimed at the identification of the molecular factors associated with disease relapse and their further investigation as therapeutically exploitable targets.
Methods
Analyses were conducted on formalin-fixed paraffin-embedded tissues of the primary tumors of relapsed (cases) and not relapsed (controls) HER2+ BC patients treated with adjuvant trastuzumab. The nCounter Human Breast Cancer Panel 360 was used. Logistic regression and partitioning around medoids were employed to identify the genes associated with disease recurrence. Cytotoxicity experiments using trastuzumab-resistant cell lines and a network pharmacology approach were carried out to investigate drug efficacy.
Results
A total of 52 patients (26 relapsed and 26 not relapsed) were analyzed. We found that a higher expression of HDAC6 was significantly associated with an increased risk of recurrence, with an adjusted OR of 3.20 (95% CI 1.38–9.91, p = 0.016). Then, we investigated the cytotoxic activity of the selective HDAC6 inhibitor Nexturastat A (NextA) on HER2+ cell lines, which were both sensitive and trastuzumab-resistant. A sub-cytotoxic concentration of NextA, combined with trastuzumab, showed a synergistic effect on BC cell lines. Finally, using a network pharmacology approach, we identified HSP90AA1 as the putative molecular candidate responsible for the synergism observed in vitro.
Conclusions
Our findings encourage the exploration of the role of HDAC6 as a prognostic factor and the combinatorial use of HDAC6 selective inhibitors combined with trastuzumab in HER2+ BC, in particular for those patients experiencing drug resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
- Pathology Unit, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy.
- Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, Italy.
- Department of Hematology and Sciences Oncology, Institute of Haematology "L. and A. Seràgnoli", S. Orsola University Hospital, 40138 Bologna, Italy.
ORCID-Profile: Michela Cortesi, Sara Bravaccini, Sara Ravaioli, William Balzi, Francesca Pirini, Paola Possanzini, Michela Palleschi, Roberta Maltoni
Förderung
- Ricerca Corrente by the Italian Ministry of Health
- Italian Ministry of Health
Zitieren
APA
Cortesi, M., Bravaccini, S., Ravaioli, S., Petracci, E., Angeli, D., Tumedei, M. M., Balzi, W., Pirini, F., Zanoni, M., Possanzini, P., Rocca, A., Palleschi, M., Ulivi, P., Martinelli, G., & Maltoni, R. (2024). HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer. Cancers, 16(22), 3752. https://doi.org/10.3390/cancers16223752
Vancouver
Cortesi M, Bravaccini S, Ravaioli S, Petracci E, Angeli D, Tumedei MM, et al. HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer. Cancers. 2024;16(22):3752. doi:10.3390/cancers16223752
BibTeX
@article{Cortesi2024,
author = {Cortesi, Michela and Bravaccini, Sara and Ravaioli, Sara and Petracci, Elisabetta and Angeli, Davide and Tumedei, Maria Maddalena and Balzi, William and Pirini, Francesca and Zanoni, Michele and Possanzini, Paola and Rocca, Andrea and Palleschi, Michela and Ulivi, Paola and Martinelli, Giovanni and Maltoni, Roberta},
title = {HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer},
journal = {Cancers},
year = {2024},
volume = {16},
number = {22},
pages = {3752},
doi = {10.3390/cancers16223752}
}
EUVIMED